These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
264 related items for PubMed ID: 1985787
1. Interaction of hyperthermia and cis-diamminedichloroplatinum(II) alone or combined with radiation in a C3H mammary carcinoma in vivo. Overgaard J, Radacic MM, Grau C. Cancer Res; 1991 Jan 15; 51(2):707-11. PubMed ID: 1985787 [Abstract] [Full Text] [Related]
2. Interaction with hyperthermia of tetrachloroplatinum(II)(Nile blue)2 and tetrachloroplatinum(II)(neutral red)2 in EMT6 murine cells and the murine FSaIIC fibrosarcoma. Herman TS, Teicher BA, Pfeffer MR, Khandekar VS, Korbut TT. Cancer Res; 1990 Jul 01; 50(13):3826-31. PubMed ID: 2354434 [Abstract] [Full Text] [Related]
4. Combined modality therapy with bleomycin, hyperthermia, and radiation. Teicher BA, Herman TS, Holden SA. Cancer Res; 1988 Nov 15; 48(22):6291-7. PubMed ID: 2460220 [Abstract] [Full Text] [Related]
5. Enhancement of cisplatin sensitivity of quiescent cells in solid tumors by combined treatment with tirapazamine and low-temperature hyperthermia. Masunaga S, Ono K, Hori H, Akaboshi M, Kawai K, Suzuki M, Kinashi Y, Kasai S, Nagasawa H, Uto Y. Radiat Med; 1998 Nov 15; 16(6):441-8. PubMed ID: 9929144 [Abstract] [Full Text] [Related]
7. Increased therapeutic gain of combined cis-diamminedichloroplatinum (II) and whole body hyperthermia therapy by optimal heat/drug scheduling. Baba H, Siddik ZH, Strebel FR, Jenkins GN, Bull JM. Cancer Res; 1989 Dec 15; 49(24 Pt 1):7041-4. PubMed ID: 2582445 [Abstract] [Full Text] [Related]
9. Response of mammary tumors of C3H/He mice to hyperthermia and bleomycin in vivo. Ma F, Hiraoka M, Jo S, Akuta K, Nishimura Y, Takahashi M, Abe M. Radiat Med; 1985 Dec 15; 3(4):230-3. PubMed ID: 2425397 [Abstract] [Full Text] [Related]
12. Sequencing of trimodality therapy [cis-diamminedichloroplatinum(II)/hyperthermia/radiation] as determined by tumor growth delay and tumor cell survival in the FSaIIC fibrosarcoma. Herman TS, Teicher BA. Cancer Res; 1988 May 15; 48(10):2693-7. PubMed ID: 3359430 [Abstract] [Full Text] [Related]
13. Lack of differential radiosensitization of hypoxic cells in a mouse tumor at low radiation doses per fraction by cisplatin. Sun JR, Brown JM. Radiat Res; 1993 Feb 15; 133(2):252-6. PubMed ID: 8438067 [Abstract] [Full Text] [Related]
14. Effects of RSR13 and oxygen on the cytotoxicity of cisplatin and carboplatin to EMT6 mouse mammary tumor cells in vitro and in vivo. Donnelly ET, Kelley M, Rockwell S. Cancer Chemother Pharmacol; 2004 Jan 15; 53(1):43-50. PubMed ID: 14574460 [Abstract] [Full Text] [Related]
16. 4'-Epi-doxorubicin and hyperthermia in a murine mammary carcinoma: influence of the dose and fractionation. Cividalli A, Danesi DT, Altavista P, Bonanni M, Persiani D, Segre L, Cruciani G. Anticancer Res; 1995 Jan 15; 15(3):739-43. PubMed ID: 7645951 [Abstract] [Full Text] [Related]
17. Combination of nicotinamide and hyperthermia to eliminate radioresistant chronically and acutely hypoxic tumor cells. Horsman MR, Chaplin DJ, Overgaard J. Cancer Res; 1990 Dec 01; 50(23):7430-6. PubMed ID: 2147577 [Abstract] [Full Text] [Related]
20. Histopathological changes in transplanted mouse mammary carcinoma following hyperthermia with or without radiation. Jo S, Hiraoka M, Akuta K, Nishimura Y, Furuta M, Takahashi M, Abe M. Jpn J Cancer Res; 1986 Nov 01; 77(11):1095-101. PubMed ID: 3098719 [Abstract] [Full Text] [Related] Page: [Next] [New Search]